Document Type
Article
Publication Date
6-4-2020
Keywords
JGM, JMG, JAXCC, Animals, Betacoronavirus, Coronavirus Infections, Disease Models, Animal, Humans, Mice, Mice, Inbred C57BL, Mice, Transgenic, Pandemics, Peptidyl-Dipeptidase A, Pneumonia, Viral, Promoter Regions, Genetic, Protein Binding, Receptors, Virus
JAX Source
Hum Genomics Jun 4; 14(1):20
Volume
14
Issue
1
First Page
20
Last Page
20
ISSN
1479-7364
PMID
32498696
DOI
https://doi.org/10.1186/s40246-020-00272-6
Abstract
Coronavirus disease 2019 (COVID-19) is a declared pandemic that is spreading all over the world at a dreadfully fast rate. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the pathogen of COVID-19, infects the human body using angiotensin-converting enzyme 2 (ACE2) as a receptor identical to the severe acute respiratory syndrome (SARS) pandemic that occurred in 2002-2003. SARS-CoV-2 has a higher binding affinity to human ACE2 than to that of other species. Animal models that mimic the human disease are highly essential to develop therapeutics and vaccines against COVID-19. Here, we review transgenic mice that express human ACE2 in the airway and other epithelia and have shown to develop a rapidly lethal infection after intranasal inoculation with SARS-CoV, the pathogen of SARS. This literature review aims to present the importance of utilizing the human ACE2 transgenic mouse model to better understand the pathogenesis of COVID-19 and develop both therapeutics and vaccines.
Recommended Citation
Lutz C,
Maher L,
Lee C,
Kang W.
COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice. Hum Genomics Jun 4; 14(1):20
Comments
This article is licensed under a Creative Commons Attribution 4.0 International License.